首页 > 最新文献

Federal practitioner : for the health care professionals of the VA, DoD, and PHS最新文献

英文 中文
A Case of Metastatic Chromophobe Renal Cell Carcinoma Masked as Suspected Hepatic Abscesses. 一例疑似肝脓肿的转移性色素性肾细胞癌
Pub Date : 2024-05-01 Epub Date: 2024-03-20 DOI: 10.12788/fp.0462
Jake A Cresta, Michael A Pavio, Jamie L Lombardo, John G McCarthy, Allison M Bush

Background: Characterizing multiple hepatic lesions on cross-sectional imaging, particularly differentiating abscesses from metastatic lesions, can be challenging.

Case presentation: A male aged 53 years with a history of chromophobe renal cell carcinoma presented with fevers and abdominal pain and was found to have multiple hepatic lesions concerning for hepatic abscesses. The lesions initially evaded diagnosis on imaging, laboratory tests, and biopsy, but ultimately were determined to be a rare case of metastatic chromophobe renal cell carcinoma of the liver.

Conclusions: The finding of multiple new liver lesions on imaging during a febrile illness is concerning for hepatic abscess or malignancy, which can be difficult to diagnose with imaging alone. Differentiation between infectious and neoplastic etiologies may require additional imaging and/or tissue sampling.

背景:在横断面成像上确定多发性肝脏病变的特征,尤其是区分脓肿和转移性病变,可能具有挑战性:病例介绍:一名 53 岁的男性,曾患嗜铬细胞肾癌,因发热和腹痛就诊,被发现有多个肝脏病变,疑似肝脓肿。这些病变最初无法通过影像学检查、实验室检查和活检确诊,但最终被确定为罕见的肝脏转移性嗜铬肾细胞癌:结论:在发热期间通过影像学检查发现多个新的肝脏病变可能是肝脓肿或恶性肿瘤,仅通过影像学检查很难确诊。区分感染性病因和肿瘤性病因可能需要额外的影像学检查和/或组织取样。
{"title":"A Case of Metastatic Chromophobe Renal Cell Carcinoma Masked as Suspected Hepatic Abscesses.","authors":"Jake A Cresta, Michael A Pavio, Jamie L Lombardo, John G McCarthy, Allison M Bush","doi":"10.12788/fp.0462","DOIUrl":"10.12788/fp.0462","url":null,"abstract":"<p><strong>Background: </strong>Characterizing multiple hepatic lesions on cross-sectional imaging, particularly differentiating abscesses from metastatic lesions, can be challenging.</p><p><strong>Case presentation: </strong>A male aged 53 years with a history of chromophobe renal cell carcinoma presented with fevers and abdominal pain and was found to have multiple hepatic lesions concerning for hepatic abscesses. The lesions initially evaded diagnosis on imaging, laboratory tests, and biopsy, but ultimately were determined to be a rare case of metastatic chromophobe renal cell carcinoma of the liver.</p><p><strong>Conclusions: </strong>The finding of multiple new liver lesions on imaging during a febrile illness is concerning for hepatic abscess or malignancy, which can be difficult to diagnose with imaging alone. Differentiation between infectious and neoplastic etiologies may require additional imaging and/or tissue sampling.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 2","pages":"S34-S37"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving Fecal Immunochemical Test Collection for Colorectal Cancer Screening During the COVID-19 Pandemic. 在 COVID-19 大流行期间改进大肠癌筛查中粪便免疫化学检验的采集。
Pub Date : 2024-05-01 Epub Date: 2024-05-15 DOI: 10.12788/fp.0455
Shruthi Narasimha, Sukhjinder Chauhan, Roger Nehaul, Jeffrey Cummings, Susan Wright, Alexis Patterson, Raymond Mullins, William Messina, Brian Zilka, Ana Kraus

Background: Colonoscopy is a first-line method for colorectal cancer (CRC) screening. However, cost-effective noninvasive tests, such as high-sensitivity guaiac-based fecal occult blood test (gFOBT) and fecal immunochemical test (FIT), are also used. The COVID-19 pandemic had a substantial negative impact on CRC screening rates. The James A. Haley Veterans Affairs Hospital (JAHVAH) continued socially distant CRC screening using FITs, but encountered inefficiencies due to high rates of incorrectly collected FIT samples. A quality improvement (QI) project was conducted to increase correctly collected and testable FIT kits upon initial laboratory submission.

Observations: The ambulatory QI project sought out root causes for incorrectly returned FITs and proposed Plan-Do-Study-Act (PDSA) cycles based on a series of approved action plans. A multidisciplinary team of laboratory, nursing, administrative, and primary care staff worked together to discover 6 major root causes. Our multipronged PDSA cycle attempted to set up redundant patient reminders, centralize the FIT dispersal process, and make the patient-FIT interface more user-friendly. All PDSA solutions were implemented over 4 months. Lack of collection date was the most common reason for incorrectly returned FIT kits and the focus of PDSA improvements. The rate of FITs with missing collection dates dropped from 24% prior to PDSA to 14% in April 2021. The rate of correctly returned FIT kits rose from 38% before the project to 72% afterwards, surpassing the 20% improvement goal.

Conclusions: FIT is a useful method for CRC screening that can be particularly helpful when in-person visits are limited, as seen during the COVID-19 pandemic. The increase in demand for FITs during the pandemic revealed process deficiencies and gave JAHVAH an opportunity to improve workflow.

背景:结肠镜检查是结直肠癌(CRC)筛查的一线方法。然而,高灵敏度愈创木酚粪便潜血试验(gFOBT)和粪便免疫化学试验(FIT)等经济有效的非侵入性检查也在使用。COVID-19 大流行对 CRC 筛查率产生了很大的负面影响。James A. Haley 退伍军人事务医院 (James A. Haley Veterans Affairs Hospital,JAHVAH) 继续在社会上使用 FIT 进行远距离 CRC 筛查,但由于 FIT 样本采集错误率较高,导致筛查效率低下。该医院开展了一项质量改进(QI)项目,以提高实验室初次提交的 FIT 套件的正确采集率和可检测率:门诊质量改进项目找出了错误退回 FIT 的根本原因,并根据一系列已获批准的行动计划提出了 "计划-实施-研究-行动"(PDSA)循环。由实验室、护理、行政和基础护理人员组成的多学科团队共同努力,发现了 6 个主要的根本原因。我们多管齐下的 PDSA 循环尝试设置多余的患者提醒、集中 FIT 分散流程,并使患者-FIT 界面更加友好。所有 PDSA 解决方案均在 4 个月内实施完毕。缺少采集日期是错误退回 FIT 套件的最常见原因,也是 PDSA 改进的重点。缺少采集日期的 FIT 比例从实施 PDSA 之前的 24% 降至 2021 年 4 月的 14%。正确退回 FIT 工具包的比率从项目实施前的 38% 上升到项目实施后的 72%,超过了 20% 的改进目标:结论:FIT 是一种有效的 CRC 筛查方法,尤其是在 COVID-19 大流行期间,当上门服务受到限制时,这种方法尤其有用。大流行期间对 FIT 需求的增加暴露了流程的不足,为 JAHVAH 提供了改进工作流程的机会。
{"title":"Improving Fecal Immunochemical Test Collection for Colorectal Cancer Screening During the COVID-19 Pandemic.","authors":"Shruthi Narasimha, Sukhjinder Chauhan, Roger Nehaul, Jeffrey Cummings, Susan Wright, Alexis Patterson, Raymond Mullins, William Messina, Brian Zilka, Ana Kraus","doi":"10.12788/fp.0455","DOIUrl":"10.12788/fp.0455","url":null,"abstract":"<p><strong>Background: </strong>Colonoscopy is a first-line method for colorectal cancer (CRC) screening. However, cost-effective noninvasive tests, such as high-sensitivity guaiac-based fecal occult blood test (gFOBT) and fecal immunochemical test (FIT), are also used. The COVID-19 pandemic had a substantial negative impact on CRC screening rates. The James A. Haley Veterans Affairs Hospital (JAHVAH) continued socially distant CRC screening using FITs, but encountered inefficiencies due to high rates of incorrectly collected FIT samples. A quality improvement (QI) project was conducted to increase correctly collected and testable FIT kits upon initial laboratory submission.</p><p><strong>Observations: </strong>The ambulatory QI project sought out root causes for incorrectly returned FITs and proposed Plan-Do-Study-Act (PDSA) cycles based on a series of approved action plans. A multidisciplinary team of laboratory, nursing, administrative, and primary care staff worked together to discover 6 major root causes. Our multipronged PDSA cycle attempted to set up redundant patient reminders, centralize the FIT dispersal process, and make the patient-FIT interface more user-friendly. All PDSA solutions were implemented over 4 months. Lack of collection date was the most common reason for incorrectly returned FIT kits and the focus of PDSA improvements. The rate of FITs with missing collection dates dropped from 24% prior to PDSA to 14% in April 2021. The rate of correctly returned FIT kits rose from 38% before the project to 72% afterwards, surpassing the 20% improvement goal.</p><p><strong>Conclusions: </strong>FIT is a useful method for CRC screening that can be particularly helpful when in-person visits are limited, as seen during the COVID-19 pandemic. The increase in demand for FITs during the pandemic revealed process deficiencies and gave JAHVAH an opportunity to improve workflow.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 2","pages":"S29-S37"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
3D Printing for the Development of Palatal Defect Prosthetics. 3D 打印技术用于开发腭部缺损修复体。
Pub Date : 2024-05-01 Epub Date: 2024-05-11 DOI: 10.12788/fp.0464
Christian Calderon, Autreen Golzar, Stephen Marcott, Kyle Gifford, Sandy Napel, Dominik Fleischmann, Fred M Baik, Thomas F Osborne, Andrey Finegersh, Davud Sirjani

Background: Three-dimensional (3D) printing has emerged as a promising new technology for the development of surgical prosthetics. Research in orthopedic surgery has demonstrated that using 3D printed customized prosthetics results in more precise implant placements and better patient outcomes. However, there has been little research on implementing customized 3D printed prosthetics in otolaryngology. The program sought to determine whether computed tomography (CT) serves as feasible templates to construct 3D printed palatal obturator prosthetics for defects in patients who have been treated for head and neck cancers.

Observations: A retrospective review of patients with palatal defects was conducted and identified 1 patient with high quality CTs compatible with 3D modeling. CTs of the patient's craniofacial anatomy were used to develop a 3D model and a Formlabs 3B+ printer printed the palatal prosthetic. We successfully developed and produced an individualized prosthetic using CTs from a veteran with head and neck deformities caused by cancer treatment who was previously treated at the Veterans Affairs Palo Alto Health Care System. This project was successful in printing patient-specific implants using CT reproductions of the patient's craniofacial anatomy, particularly of the palate. The program was a proof of concept and the implant we created was not used on the patient.

Conclusions: Customized 3D printed implants may allow otolaryngologists to enhance the performance and efficiency of surgeries and better rehabilitate and reconstruct craniofacial deformities to restore appearance and function to patients. Additional research will strive to enhance the therapeutic potential of these prosthetics to serve as low-cost, patient-specific implants.

背景:三维(3D)打印技术已成为开发外科假体的一项前景广阔的新技术。骨科手术方面的研究表明,使用三维打印定制假体可以使植入物的位置更精确,患者的治疗效果更好。然而,在耳鼻喉科中使用定制 3D 打印假体的研究却很少。该计划旨在确定计算机断层扫描(CT)是否可作为可行的模板,为接受过头颈部癌症治疗的患者构建3D打印腭钝器假体:我们对患有腭部缺损的患者进行了回顾性检查,发现 1 名患者的高质量 CT 与 3D 建模相匹配。患者颅面部解剖结构的 CT 图像被用于开发三维模型,Formlabs 3B+ 打印机打印出了腭假体。我们利用一名曾在退伍军人事务帕洛阿尔托医疗保健系统接受治疗的因癌症治疗导致头颈部畸形的退伍军人的 CT 图像,成功开发并制作了个性化假体。该项目成功地利用患者颅面部解剖结构(尤其是腭部)的 CT 复制品打印出了患者专用的假体。该项目只是概念验证,我们制作的植入体并未用于患者:定制的三维打印植入物可以让耳鼻喉科医生提高手术的效果和效率,更好地康复和重建颅面畸形,恢复患者的外观和功能。其他研究将努力提高这些假体的治疗潜力,使其成为低成本、针对特定患者的植入体。
{"title":"3D Printing for the Development of Palatal Defect Prosthetics.","authors":"Christian Calderon, Autreen Golzar, Stephen Marcott, Kyle Gifford, Sandy Napel, Dominik Fleischmann, Fred M Baik, Thomas F Osborne, Andrey Finegersh, Davud Sirjani","doi":"10.12788/fp.0464","DOIUrl":"10.12788/fp.0464","url":null,"abstract":"<p><strong>Background: </strong>Three-dimensional (3D) printing has emerged as a promising new technology for the development of surgical prosthetics. Research in orthopedic surgery has demonstrated that using 3D printed customized prosthetics results in more precise implant placements and better patient outcomes. However, there has been little research on implementing customized 3D printed prosthetics in otolaryngology. The program sought to determine whether computed tomography (CT) serves as feasible templates to construct 3D printed palatal obturator prosthetics for defects in patients who have been treated for head and neck cancers.</p><p><strong>Observations: </strong>A retrospective review of patients with palatal defects was conducted and identified 1 patient with high quality CTs compatible with 3D modeling. CTs of the patient's craniofacial anatomy were used to develop a 3D model and a Formlabs 3B+ printer printed the palatal prosthetic. We successfully developed and produced an individualized prosthetic using CTs from a veteran with head and neck deformities caused by cancer treatment who was previously treated at the Veterans Affairs Palo Alto Health Care System. This project was successful in printing patient-specific implants using CT reproductions of the patient's craniofacial anatomy, particularly of the palate. The program was a proof of concept and the implant we created was not used on the patient.</p><p><strong>Conclusions: </strong>Customized 3D printed implants may allow otolaryngologists to enhance the performance and efficiency of surgeries and better rehabilitate and reconstruct craniofacial deformities to restore appearance and function to patients. Additional research will strive to enhance the therapeutic potential of these prosthetics to serve as low-cost, patient-specific implants.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 2","pages":"S3-S7"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Anti-Agitation Medication Prescribing Patterns by Age in the Emergency Department. 评估急诊科按年龄分列的抗牙痛药物处方模式。
Pub Date : 2024-04-01 Epub Date: 2024-02-21 DOI: 10.12788/fp.0456
Lisa Hsi, Shannon Ruiz

Background: Acute agitation frequently occurs in the emergency department. Appropriate management is critical for the safety of all parties involved. Benzodiazepines and antipsychotics are commonly used for agitation, but safety concerns exist with these medications in older adults, even with acute use. The purpose of this study was to compare prescribing practices of anti-agitation medications between adults aged 18 to 64 years and those aged ≥ 65 years.

Methods: This study was a retrospective chart review of patients who presented to the Veteran Affairs Southern Nevada Healthcare System emergency department and received haloperidol, droperidol, lorazepam, olanzapine, or ziprasidone from August 1, 2019, to July 31, 2022. Veterans were excluded if they had alcohol intoxication, alcohol withdrawal, benzodiazepine withdrawal, or medication administration unrelated to agitation. Safety outcomes included oxygen saturation < 95%, supplemental oxygen use, intubation, QTc prolongation, and new hypotension within 1 hour of medication administration.

Results: For the 232 patients who met inclusion criteria, baseline characteristics differed significantly. When comparing patients aged 18 to 64 years and those aged ≥ 65 years, the younger cohort had higher rates of substance use disorder diagnosis (55.3% vs 27.5%, P < .001), positive urine drug screen (69.7% vs 22.5%, P < .001), and 72-hour legal hold (59.9% vs 32.5%, P < .001), and lower rates of cognitive impairment or dementia (0.7% vs 48.8%, P < .001), and altered mental status-related diagnosis (2.0% vs 18.8%, P < .001). Anti-agitation medication selection significantly differed based on age (P = .02). Other than lorazepam (P = .007), no significant differences were noted in the dose ordered. No significant differences were observed for safety outcomes or additional anti-agitation doses.

Conclusions: Anti-agitation prescribing practices may differ between adults aged 18 to 64 years and those aged ≥ 65 years. The findings of this study also suggest that the most common agitation etiologies may differ based on patient age. Additional higher-quality studies are needed to further explore acute agitation in older adults.

背景:急性躁动经常发生在急诊科。适当的处理对所有相关人员的安全至关重要。苯二氮卓类药物和抗精神病药物是治疗躁动的常用药物,但这些药物对老年人的安全性存在担忧,即使是急性用药也是如此。本研究的目的是比较 18 至 64 岁的成年人和年龄≥ 65 岁的成年人抗激动药物的处方做法:本研究是对 2019 年 8 月 1 日至 2022 年 7 月 31 日期间在退伍军人事务南内华达医疗保健系统急诊科就诊并接受氟哌啶醇、屈哌利多、劳拉西泮、奥氮平或齐拉西酮治疗的患者进行的回顾性病历审查。如果退伍军人存在酒精中毒、酒精戒断、苯二氮卓类药物戒断或与躁动无关的用药情况,则排除在外。安全结果包括血氧饱和度<95%、补充氧气使用、插管、QTc延长以及用药后1小时内出现新的低血压:符合纳入标准的 232 名患者的基线特征差异显著。将年龄在 18 至 64 岁的患者与年龄≥ 65 岁的患者进行比较,年轻组群的药物使用障碍诊断率更高(55.3% vs 27.5%,P < .001),尿液药物筛查阳性率更高(69.7% vs 22.5%,P < .001)和 72 小时法定保留期(59.9% vs 32.5%,P < .001),而认知障碍或痴呆(0.7% vs 48.8%,P < .001)和精神状态改变相关诊断(2.0% vs 18.8%,P < .001)的比例较低。抗焦虑药物的选择因年龄而有明显差异(P = .02)。除了劳拉西泮(P = .007)外,其他药物的剂量没有明显差异。在安全性结果或额外抗凝药物剂量方面也未发现明显差异:结论:18 至 64 岁的成年人与年龄≥ 65 岁的成年人在抗焦虑处方方面可能存在差异。本研究结果还表明,最常见的激越病因可能因患者年龄而异。需要进行更多高质量的研究,以进一步探讨老年人的急性躁动问题。
{"title":"Evaluation of Anti-Agitation Medication Prescribing Patterns by Age in the Emergency Department.","authors":"Lisa Hsi, Shannon Ruiz","doi":"10.12788/fp.0456","DOIUrl":"10.12788/fp.0456","url":null,"abstract":"<p><strong>Background: </strong>Acute agitation frequently occurs in the emergency department. Appropriate management is critical for the safety of all parties involved. Benzodiazepines and antipsychotics are commonly used for agitation, but safety concerns exist with these medications in older adults, even with acute use. The purpose of this study was to compare prescribing practices of anti-agitation medications between adults aged 18 to 64 years and those aged ≥ 65 years.</p><p><strong>Methods: </strong>This study was a retrospective chart review of patients who presented to the Veteran Affairs Southern Nevada Healthcare System emergency department and received haloperidol, droperidol, lorazepam, olanzapine, or ziprasidone from August 1, 2019, to July 31, 2022. Veterans were excluded if they had alcohol intoxication, alcohol withdrawal, benzodiazepine withdrawal, or medication administration unrelated to agitation. Safety outcomes included oxygen saturation < 95%, supplemental oxygen use, intubation, QTc prolongation, and new hypotension within 1 hour of medication administration.</p><p><strong>Results: </strong>For the 232 patients who met inclusion criteria, baseline characteristics differed significantly. When comparing patients aged 18 to 64 years and those aged ≥ 65 years, the younger cohort had higher rates of substance use disorder diagnosis (55.3% vs 27.5%, <i>P</i> < .001), positive urine drug screen (69.7% vs 22.5%, <i>P</i> < .001), and 72-hour legal hold (59.9% vs 32.5%, <i>P</i> < .001), and lower rates of cognitive impairment or dementia (0.7% vs 48.8%, <i>P</i> < .001), and altered mental status-related diagnosis (2.0% vs 18.8%, <i>P</i> < .001). Anti-agitation medication selection significantly differed based on age (<i>P</i> = .02). Other than lorazepam (<i>P</i> = .007), no significant differences were noted in the dose ordered. No significant differences were observed for safety outcomes or additional anti-agitation doses.</p><p><strong>Conclusions: </strong>Anti-agitation prescribing practices may differ between adults aged 18 to 64 years and those aged ≥ 65 years. The findings of this study also suggest that the most common agitation etiologies may differ based on patient age. Additional higher-quality studies are needed to further explore acute agitation in older adults.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 1","pages":"S16-S21"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Underlying Mental Illness and Risk of Severe Outcomes Associated With COVID-19. 与 COVID-19 相关的潜在精神疾病和严重后果风险。
Pub Date : 2024-04-01 Epub Date: 2024-04-15 DOI: 10.12788/fp.0469
Angelica Castro, Hong-Yen Vi

Background: According to the Centers for Disease Control and Prevention, depression and schizophrenia, among other conditions, put individuals at high risk for severe COVID-19 infection. Patients at high risk often are eligible for outpatient therapies, such as antiviral and monoclonal antibody therapies, to prevent severe infection. However, depression and schizophrenia are not considered risk factors for severe COVID-19 infection at the Captain James A. Lovell Federal Health Care Center in North Chicago, Illinois, making patients with these conditions ineligible for outpatient therapy unless they have another high-risk condition.

Methods: This retrospective cohort study assessed outcomes among patients with mild-to-moderate COVID-19 to determine whether depression and/or schizophrenia impacted the risk of severe disease or negative outcomes. The primary outcome was severe COVID-19 outcomes defined as hospitalization, admission to the intensive care unit, intubation or mechanical ventilation, or death within 30 days of infection.

Results: Patients with depression or schizophrenia had more hospitalizations and deaths, but this difference was not statistically significant (P = .36). Death within 30 days of COVID-19 infection only occurred in patients with depression or schizophrenia.

Conclusions: Although there were more hospitalizations and deaths from COVID-19 within 30 days of infection among patients with depression and schizophrenia compared with individuals without these disorders, this finding was not statistically significant.

背景:根据美国疾病控制与预防中心(Centers for Disease Control and Prevention)的资料,抑郁症和精神分裂症等疾病会使患者面临严重感染 COVID-19 的高风险。高危患者通常有资格接受门诊治疗,如抗病毒和单克隆抗体治疗,以预防严重感染。然而,在伊利诺伊州北芝加哥的詹姆斯-A-洛弗尔上尉联邦医疗保健中心,抑郁症和精神分裂症并不被视为严重感染 COVID-19 的风险因素,因此患有这些疾病的患者没有资格接受门诊治疗,除非他们患有其他高风险疾病:这项回顾性队列研究评估了轻度至中度 COVID-19 患者的预后,以确定抑郁症和/或精神分裂症是否会影响重症风险或不良预后。主要结果是严重的COVID-19结果,即感染后30天内住院、入住重症监护室、插管或机械通气或死亡:结果:抑郁症或精神分裂症患者的住院和死亡人数较多,但差异无统计学意义(P = .36)。只有抑郁症或精神分裂症患者在感染 COVID-19 后 30 天内死亡:结论:尽管与无抑郁症和精神分裂症的患者相比,抑郁症和精神分裂症患者在感染 COVID-19 后 30 天内住院和死亡的人数更多,但这一结果并无统计学意义。
{"title":"Underlying Mental Illness and Risk of Severe Outcomes Associated With COVID-19.","authors":"Angelica Castro, Hong-Yen Vi","doi":"10.12788/fp.0469","DOIUrl":"10.12788/fp.0469","url":null,"abstract":"<p><strong>Background: </strong>According to the Centers for Disease Control and Prevention, depression and schizophrenia, among other conditions, put individuals at high risk for severe COVID-19 infection. Patients at high risk often are eligible for outpatient therapies, such as antiviral and monoclonal antibody therapies, to prevent severe infection. However, depression and schizophrenia are not considered risk factors for severe COVID-19 infection at the Captain James A. Lovell Federal Health Care Center in North Chicago, Illinois, making patients with these conditions ineligible for outpatient therapy unless they have another high-risk condition.</p><p><strong>Methods: </strong>This retrospective cohort study assessed outcomes among patients with mild-to-moderate COVID-19 to determine whether depression and/or schizophrenia impacted the risk of severe disease or negative outcomes. The primary outcome was severe COVID-19 outcomes defined as hospitalization, admission to the intensive care unit, intubation or mechanical ventilation, or death within 30 days of infection.</p><p><strong>Results: </strong>Patients with depression or schizophrenia had more hospitalizations and deaths, but this difference was not statistically significant (<i>P</i> = .36). Death within 30 days of COVID-19 infection only occurred in patients with depression or schizophrenia.</p><p><strong>Conclusions: </strong>Although there were more hospitalizations and deaths from COVID-19 within 30 days of infection among patients with depression and schizophrenia compared with individuals without these disorders, this finding was not statistically significant.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 1","pages":"S6-S9"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preparing Veterans Health Administration Psychologists to Meet the Complex Needs of Aging Veterans. 培养退伍军人健康管理局的心理学家,以满足老龄退伍军人的复杂需求。
Pub Date : 2024-04-01 Epub Date: 2024-04-15 DOI: 10.12788/fp.0466
Christine E Gould, Rachel L Rodriguez, Jeffrey J Gregg, Kyle Page, Luis Melendez, Joseph R Douglas, Johnny Lewis, B Josea Kramer

Background: There are significant workforce shortages for geriatric mental health care. The imbalance is particularly pronounced in the Veterans Health Administration (VHA) due to the large number of aging veterans receiving care. Workforce-based educational programs are needed to train existing clinicians to meet the mental health needs of aging veterans.

Observations: This article describes an expansion of the Geriatric Scholars Program to train VHA psychologists to care for aging veterans. The multicomponent program includes an introductory course and opportunities to apply geriatric knowledge and skills through quality improvement initiatives. The Geriatric Scholars Program-Psychology Track evolved to incorporate ongoing specialized elective learning opportunities for scholars. A webinar series extends the educational programs to reach the entire VHA workforce.

Conclusions: The Geriatric Scholars Program-Psychology Track represents a longitudinal educational approach to training VHA psychologists in clinical geropsychology. Other community-based organizations can use this model to construct and implement similar programs.

背景:老年心理健康护理人员严重短缺。由于接受治疗的老龄退伍军人人数众多,这种不平衡在退伍军人健康管理局(VHA)尤为明显。我们需要基于劳动力的教育计划来培训现有的临床医生,以满足老龄退伍军人的心理健康需求:本文介绍了老年病学者项目的扩展情况,该项目旨在培训退伍军人事务部的心理医生,以照顾高龄退伍军人。该计划由多个部分组成,包括入门课程和通过质量改进措施应用老年病学知识和技能的机会。老年病学者计划--心理学方向不断发展,为学者们提供了持续的专业选修学习机会。网络研讨会系列扩大了教育计划的范围,使整个退伍军人事务部的工作人员都能参与其中:结论:老年学者项目--心理学方向代表了在临床老年心理学方面培训退伍军人管理局心理学家的一种纵向教育方法。其他社区组织也可以利用这一模式来构建和实施类似的计划。
{"title":"Preparing Veterans Health Administration Psychologists to Meet the Complex Needs of Aging Veterans.","authors":"Christine E Gould, Rachel L Rodriguez, Jeffrey J Gregg, Kyle Page, Luis Melendez, Joseph R Douglas, Johnny Lewis, B Josea Kramer","doi":"10.12788/fp.0466","DOIUrl":"10.12788/fp.0466","url":null,"abstract":"<p><strong>Background: </strong>There are significant workforce shortages for geriatric mental health care. The imbalance is particularly pronounced in the Veterans Health Administration (VHA) due to the large number of aging veterans receiving care. Workforce-based educational programs are needed to train existing clinicians to meet the mental health needs of aging veterans.</p><p><strong>Observations: </strong>This article describes an expansion of the Geriatric Scholars Program to train VHA psychologists to care for aging veterans. The multicomponent program includes an introductory course and opportunities to apply geriatric knowledge and skills through quality improvement initiatives. The Geriatric Scholars Program-Psychology Track evolved to incorporate ongoing specialized elective learning opportunities for scholars. A webinar series extends the educational programs to reach the entire VHA workforce.</p><p><strong>Conclusions: </strong>The Geriatric Scholars Program-Psychology Track represents a longitudinal educational approach to training VHA psychologists in clinical geropsychology. Other community-based organizations can use this model to construct and implement similar programs.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 Suppl 1","pages":"S10-S15"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronicling Health Care Transformation: Federal Practitioner Looks Back 40 Years. 记录医疗变革:联邦从业者回顾 40 年。
{"title":"Chronicling Health Care Transformation: <i>Federal Practitioner</i> Looks Back 40 Years.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"41 1","pages":"4-5"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11147444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VA Home Telehealth Program for Initiating and Optimizing Heart Failure Guideline-Directed Medical Therapy. 退伍军人事务部用于启动和优化心力衰竭指南指导医疗疗法的家庭远程保健计划。
Pub Date : 2023-12-01 Epub Date: 2023-12-12 DOI: 10.12788/fp.0437
Robert Dedo, Tomasz Jurga, Johnathan Barkham

Background: Heart failure (HF) is a chronic, progressive medical condition. Evidence suggests that guideline-directed medical therapy improves both morbidity and mortality in patients with HF with reduced ejection fraction when properly optimized. Unfortunately, many patients do not receive optimized therapy, highlighting the need to optimize clinicians' methods to more effectively and efficiently initiate and titrate medical therapy.

Methods: This single-center, retrospective study evaluated the rates of drug interventions prompted by the home telehealth monitoring program for veterans with HF with reduced ejection fraction. Rates of drug interventions were evaluated among those who enrolled and those who did not enroll in the program.

Results: There were 20 drug-related interventions in the home telehealth group compared with 11 interventions for the control group. One HF-related hospitalization occurred in the home telehealth program group compared with 6 in the control group.

Conclusions: This study demonstrates the potential of home telehealth to optimize veterans' medication regimens and to reduce HF-related hospitalizations. It also provides an additional catalyst to further develop home telehealth services specifically targeted at drug therapy initiation and optimization in patients with HF with reduced ejection fraction.

背景介绍心力衰竭(HF)是一种慢性、进展性疾病。有证据表明,在适当优化的情况下,指南指导下的药物治疗可改善射血分数降低的心力衰竭患者的发病率和死亡率。遗憾的是,许多患者并没有接受优化治疗,这凸显了优化临床医生方法的必要性,以便更有效、高效地启动和滴定药物治疗:这项单中心回顾性研究评估了通过家庭远程医疗监控项目对患有射血分数减低型心房颤动的退伍军人进行药物干预的比例。对加入和未加入该计划的退伍军人的药物干预率进行了评估:结果:与对照组的 11 次干预相比,家庭远程保健组有 20 次与药物相关的干预。家庭远程保健计划组有 1 例与高血压相关的住院治疗,而对照组有 6 例:这项研究证明了家庭远程保健在优化退伍军人用药方案和减少高血压相关住院治疗方面的潜力。这项研究还为进一步发展专门针对射血分数降低的高血压患者的药物治疗启动和优化的家庭远程医疗服务提供了新的动力。
{"title":"VA Home Telehealth Program for Initiating and Optimizing Heart Failure Guideline-Directed Medical Therapy.","authors":"Robert Dedo, Tomasz Jurga, Johnathan Barkham","doi":"10.12788/fp.0437","DOIUrl":"10.12788/fp.0437","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is a chronic, progressive medical condition. Evidence suggests that guideline-directed medical therapy improves both morbidity and mortality in patients with HF with reduced ejection fraction when properly optimized. Unfortunately, many patients do not receive optimized therapy, highlighting the need to optimize clinicians' methods to more effectively and efficiently initiate and titrate medical therapy.</p><p><strong>Methods: </strong>This single-center, retrospective study evaluated the rates of drug interventions prompted by the home telehealth monitoring program for veterans with HF with reduced ejection fraction. Rates of drug interventions were evaluated among those who enrolled and those who did not enroll in the program.</p><p><strong>Results: </strong>There were 20 drug-related interventions in the home telehealth group compared with 11 interventions for the control group. One HF-related hospitalization occurred in the home telehealth program group compared with 6 in the control group.</p><p><strong>Conclusions: </strong>This study demonstrates the potential of home telehealth to optimize veterans' medication regimens and to reduce HF-related hospitalizations. It also provides an additional catalyst to further develop home telehealth services specifically targeted at drug therapy initiation and optimization in patients with HF with reduced ejection fraction.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 Suppl 6","pages":"S16-S23"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discontinuation Schedule of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease. 慢性阻塞性肺病患者停用吸入性皮质类固醇的时间表。
Pub Date : 2023-12-01 Epub Date: 2023-12-13 DOI: 10.12788/fp.0442
Molly E Steeves, Haley A Runeberg, Savannah R Johnson, Kevin C Kelly

Background: Long-term use of inhaled corticosteroids (ICSs) is associated with several potential adverse effects. While patients unlikely to benefit should stop ICS use, abrupt discontinuation may result in an increased risk of chronic obstructive pulmonary disease (COPD) exacerbation. Stepwise tapering may reduce this risk but data are limited, and there is no consensus on the likelihood of COPD exacerbations following ICS discontinuation. The North Texas Veterans Affairs Health Care System conducted a single center, retrospective cohort study to evaluate the rate of COPD exacerbations following the discontinuation of ICS therapy using different schedules of discontinuation.

Methods: Data were collected from the electronic health records of patients aged ≥ 40 years with a diagnosis of COPD who were on a stable dose of an ICS for ≥ 1 year that was subsequently discontinued with a last documented fill date between January 10, 2021 and September 1, 2021. Eligible patients were followed for COPD exacerbations that resulted in hospitalization until November 1, 2022. Descriptive statistics were used to evaluate characteristics of patients who experienced an exacerbation.

Results: Seventy-five patients were included: 5 (7%) experienced an exacerbation following ICS discontinuation. Age, sex, race, and ethnicity were similar for those patients who did vs did not have an exacerbation. Unexpectedly, the mean baseline eosinophil count for patients with an exacerbation was 92 cells/μL compared with 227.4 cells/μL for those without an exacerbation. Nine patients had their ICS tapered gradually, and none of them experienced an exacerbation.

Conclusions: Study findings suggest that there is a relatively low risk of COPD exacerbation following ICS discontinuation, regardless of whether a taper was performed. This result may indicate that it is reasonable to abruptly discontinue ICS in eligible patients.

背景:长期使用吸入式皮质类固醇(ICS)会产生一些潜在的不良反应。虽然不太可能获益的患者应停止使用 ICS,但突然停药可能会导致慢性阻塞性肺病(COPD)加重的风险增加。逐步减量可能会降低这种风险,但数据有限,而且对于停用 ICS 后慢性阻塞性肺病(COPD)加重的可能性还没有达成共识。北德克萨斯退伍军人事务医疗保健系统开展了一项单中心回顾性队列研究,以评估采用不同的停药计划停用 ICS 治疗后慢性阻塞性肺疾病的加重率:研究人员从年龄≥ 40 岁、诊断为慢性阻塞性肺病的患者的电子病历中收集数据,这些患者曾使用稳定剂量的 ICS 治疗≥ 1 年,随后停用了 ICS,最后记录的填充日期在 2021 年 1 月 10 日至 2021 年 9 月 1 日之间。在 2022 年 11 月 1 日前,对符合条件的慢性阻塞性肺病患者因慢性阻塞性肺病加重而住院治疗的情况进行随访。采用描述性统计方法评估病情恶化患者的特征:结果:共纳入 75 名患者:结果:共纳入 75 名患者:5 人(7%)在停用 ICS 后病情加重。出现与未出现病情恶化的患者的年龄、性别、种族和民族相似。意想不到的是,病情恶化患者的平均基线嗜酸性粒细胞计数为 92 cells/μL,而未出现病情恶化的患者为 227.4 cells/μL。九名患者的 ICS 逐渐减少,但没有一人出现病情加重:研究结果表明,无论是否减量,停用 ICS 后慢性阻塞性肺疾病恶化的风险相对较低。这一结果可能表明,对符合条件的患者突然停用 ICS 是合理的。
{"title":"Discontinuation Schedule of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease.","authors":"Molly E Steeves, Haley A Runeberg, Savannah R Johnson, Kevin C Kelly","doi":"10.12788/fp.0442","DOIUrl":"10.12788/fp.0442","url":null,"abstract":"<p><strong>Background: </strong>Long-term use of inhaled corticosteroids (ICSs) is associated with several potential adverse effects. While patients unlikely to benefit should stop ICS use, abrupt discontinuation may result in an increased risk of chronic obstructive pulmonary disease (COPD) exacerbation. Stepwise tapering may reduce this risk but data are limited, and there is no consensus on the likelihood of COPD exacerbations following ICS discontinuation. The North Texas Veterans Affairs Health Care System conducted a single center, retrospective cohort study to evaluate the rate of COPD exacerbations following the discontinuation of ICS therapy using different schedules of discontinuation.</p><p><strong>Methods: </strong>Data were collected from the electronic health records of patients aged ≥ 40 years with a diagnosis of COPD who were on a stable dose of an ICS for ≥ 1 year that was subsequently discontinued with a last documented fill date between January 10, 2021 and September 1, 2021. Eligible patients were followed for COPD exacerbations that resulted in hospitalization until November 1, 2022. Descriptive statistics were used to evaluate characteristics of patients who experienced an exacerbation.</p><p><strong>Results: </strong>Seventy-five patients were included: 5 (7%) experienced an exacerbation following ICS discontinuation. Age, sex, race, and ethnicity were similar for those patients who did vs did not have an exacerbation. Unexpectedly, the mean baseline eosinophil count for patients with an exacerbation was 92 cells/μL compared with 227.4 cells/μL for those without an exacerbation. Nine patients had their ICS tapered gradually, and none of them experienced an exacerbation.</p><p><strong>Conclusions: </strong>Study findings suggest that there is a relatively low risk of COPD exacerbation following ICS discontinuation, regardless of whether a taper was performed. This result may indicate that it is reasonable to abruptly discontinue ICS in eligible patients.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 12","pages":"398-403"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center. 退伍军人事务医疗中心将利拉鲁肽转换为赛马鲁肽对血糖控制和成本节约的影响。
Pub Date : 2023-12-01 Epub Date: 2023-09-22 DOI: 10.12788/fp.0413
Maiah Hardin, Fiona Adanse, Chandler Schexnayder, Janeca Malveaux, Sylvester Agbahiwe

Background: Semaglutide and liraglutide are glucagon-like peptide 1 receptor agonists (GLP-1 RAs) approved by the US Food and Drug Administration for patients with type II diabetes mellitus (T2DM). Patients with T2DM treated with liraglutide at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) were converted to semaglutide. The primary objective was to assess changes in glycemic control and cost savings that resulted from this conversion.

Methods: We conducted a retrospective chart review of veterans without retinopathy treated at MEDVAMC between March 1, 2021, and November 30, 2021, who were converted from liraglutide 0.6 mg and 1.2 mg daily to semaglutide 0.25 mg weekly (titrated to 0.5 mg weekly after 4 weeks). We compared hemoglobin A1c (HbA1c) values at baseline and 3 to 12 months following conversion to assess glycemic control. Cost savings were evaluated using outpatient pharmacy data.

Results: During the study, 411 patients were converted from liraglutide to semaglutide; 49 additional patients met the criteria for clinician education, and 14 were converted as a result. In total, 304 patients met the criteria for inclusion. At baseline, patients' mean (SD) levels included: HbA1c, 8.1% (1.5); blood glucose, 187.4 (44.2) mg/dL; and body weight, 112.9 (23.0) kg. Three to 12 months postconversion, patients' mean (SD) HbA1c significantly decreased to 7.6% (1.4) (P < .001), blood glucose decreased to 172.6 (39.0) mg/dL (P < .001), and body weight decreased to 105.2 (32.3) kg (P < .001). Cost savings exceeding $400,000 resulted from liraglutide to semaglutide conversion.

Conclusions: Conversion of liraglutide to semaglutide led to significant HbA1c decrease and weight loss and resulted in minimal changes to patients' antihyperglycemic regimen. Common adverse effects included hypoglycemia and gastrointestinal intolerance. Due to the low conversion rate of liraglutide to semaglutide following education, a more effective method of education for clinicians to promote teleretinal imaging before conversion is warranted. Lastly, although the semaglutide cost savings initiative at MEDVAMC resulted in significant savings for the institution, a full cost-effective analysis is needed for further conclusion.

背景:塞马鲁肽和利拉鲁肽是美国食品和药物管理局批准用于治疗II型糖尿病(T2DM)患者的胰高血糖素样肽1受体激动剂(GLP-1 RAs)。Michael E. DeBakey退伍军人事务医疗中心(MEDVAMC)接受利拉鲁肽治疗的T2DM患者转用了赛马鲁肽。主要目的是评估血糖控制的变化以及转换后节省的成本:我们对 2021 年 3 月 1 日至 2021 年 11 月 30 日期间在 MEDVAMC 接受治疗的无视网膜病变的退伍军人进行了回顾性病历审查,他们从每天服用利拉鲁肽 0.6 毫克和 1.2 毫克转为每周服用塞马鲁肽 0.25 毫克(4 周后滴定为每周服用 0.5 毫克)。我们比较了基线和转换后 3 至 12 个月的血红蛋白 A1c (HbA1c) 值,以评估血糖控制情况。我们还利用门诊药房数据对成本节约情况进行了评估:研究期间,411 名患者从利拉鲁肽转为塞马鲁肽;另外 49 名患者符合临床医生教育标准,14 名患者因此转为塞马鲁肽。共有 304 名患者符合纳入标准。基线时,患者的平均(标度)水平包括HbA1c,8.1% (1.5);血糖,187.4 (44.2) mg/dL;体重,112.9 (23.0) kg。转换后 3 至 12 个月,患者的平均(标清)HbA1c 显著降至 7.6% (1.4) (P < .001),血糖降至 172.6 (39.0) mg/dL (P < .001),体重降至 105.2 (32.3) kg (P < .001)。将利拉鲁肽转换为塞马鲁肽可节省超过40万美元的成本:结论:将利拉鲁肽转换为塞马鲁肽可显著降低 HbA1c 和减轻体重,对患者降糖治疗方案的改变极小。常见的不良反应包括低血糖和胃肠道不耐受。由于利拉鲁肽在接受教育后转换为塞马鲁肽的比例较低,因此有必要为临床医生提供更有效的教育方法,在转换前推广远程视网膜成像。最后,虽然 MEDVAMC 的semaglutide 成本节约计划为该机构节省了大量成本,但仍需进行全面的成本效益分析才能得出进一步结论。
{"title":"Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center.","authors":"Maiah Hardin, Fiona Adanse, Chandler Schexnayder, Janeca Malveaux, Sylvester Agbahiwe","doi":"10.12788/fp.0413","DOIUrl":"10.12788/fp.0413","url":null,"abstract":"<p><strong>Background: </strong>Semaglutide and liraglutide are glucagon-like peptide 1 receptor agonists (GLP-1 RAs) approved by the US Food and Drug Administration for patients with type II diabetes mellitus (T2DM). Patients with T2DM treated with liraglutide at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) were converted to semaglutide. The primary objective was to assess changes in glycemic control and cost savings that resulted from this conversion.</p><p><strong>Methods: </strong>We conducted a retrospective chart review of veterans without retinopathy treated at MEDVAMC between March 1, 2021, and November 30, 2021, who were converted from liraglutide 0.6 mg and 1.2 mg daily to semaglutide 0.25 mg weekly (titrated to 0.5 mg weekly after 4 weeks). We compared hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) values at baseline and 3 to 12 months following conversion to assess glycemic control. Cost savings were evaluated using outpatient pharmacy data.</p><p><strong>Results: </strong>During the study, 411 patients were converted from liraglutide to semaglutide; 49 additional patients met the criteria for clinician education, and 14 were converted as a result. In total, 304 patients met the criteria for inclusion. At baseline, patients' mean (SD) levels included: HbA<sub>1c</sub>, 8.1% (1.5); blood glucose, 187.4 (44.2) mg/dL; and body weight, 112.9 (23.0) kg. Three to 12 months postconversion, patients' mean (SD) HbA<sub>1c</sub> significantly decreased to 7.6% (1.4) (<i>P</i> < .001), blood glucose decreased to 172.6 (39.0) mg/dL (<i>P</i> < .001), and body weight decreased to 105.2 (32.3) kg (<i>P</i> < .001). Cost savings exceeding $400,000 resulted from liraglutide to semaglutide conversion.</p><p><strong>Conclusions: </strong>Conversion of liraglutide to semaglutide led to significant HbA<sub>1c</sub> decrease and weight loss and resulted in minimal changes to patients' antihyperglycemic regimen. Common adverse effects included hypoglycemia and gastrointestinal intolerance. Due to the low conversion rate of liraglutide to semaglutide following education, a more effective method of education for clinicians to promote teleretinal imaging before conversion is warranted. Lastly, although the semaglutide cost savings initiative at MEDVAMC resulted in significant savings for the institution, a full cost-effective analysis is needed for further conclusion.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 Suppl 6","pages":"S24-S30"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Federal practitioner : for the health care professionals of the VA, DoD, and PHS
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1